OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Data presented at key congresses in North America and EuropeCAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Spring House, Pennsylvania Monday, February 24, 2025, 09:00 Hrs [IST] ...